



## **Jounce Therapeutics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Friday, November 6, 2020**

October 30, 2020

CAMBRIDGE, Mass., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2020 financial results and provide a corporate update before market open on Friday, November 6, 2020. Jounce Therapeutics' management team will host a live conference call and webcast at 8:00 a.m. ET.

### **Conference Call and Webcast**

To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 8009939. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company's website at [www.jouncetx.com](http://www.jouncetx.com). The webcast will be archived and made available for replay on the company's website approximately two hours after the call and will be available for 30 days thereafter.

### **About Jounce Therapeutics**

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development-stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the EMERGE and SELECT Phase 2 trials. JTX-4014 is a PD-1 inhibitor intended for combination use in the SELECT study and with Jounce's broader pipeline. Jounce's next clinical-stage product candidate, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state. A Phase 1 trial evaluating JTX-8064 is planned to begin enrollment in the fourth quarter of 2020. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit [www.jouncetx.com](http://www.jouncetx.com).

### **Jounce Investor and Media Contacts:**

Malin Deon  
+1-857-259-3843  
[mdeon@jouncetx.com](mailto:mdeon@jouncetx.com)

Mark Yore  
+1-857-200-1255  
[myore@jouncetx.com](mailto:myore@jouncetx.com)



Source: Jounce Therapeutics, Inc.